Harmony Biosciences Holdings, Inc. (HRMY)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ: HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Harmony has violated federal securities laws.
On March 28, 2023, Scorpion Capital (“Scorpion”) published a short report on Harmony, which Scorpion described as “[o]ne of the most thoroughly corrupt healthcare schemes in recent years, deserving of criminal and political scrutiny”. Scorpion described “Harmony’s drug Wakix (pitolisant) [as] a repeat of the Seldane (terfenadine) saga, another histamine antagonist that the FDA pulled from the market and which is the poster child for cardiac toxicity via fatal QT prolongation/arrhythmia.” Scorpion asserted that it “obtained dozens of serious adverse event reports from the FDA via Freedom of Information Act requests filed over several months, and they paint a devastating picture of the drug’s risk to even young, otherwise healthy patients, including a recent sudden cardiac death, 2 weeks after starting Wakix on the day it was titrated to the highest dose.” On this news, Harmony’s stock price fell sharply during intraday trading on March 28, 2023.
If you are aware of any facts relating to this investigation or purchased Harmony shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.